The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Leadership - AECC; Altum Sequencing; Genomica; ONCOSUR
Honoraria - AstraZeneca; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; Janssen; Lilly; Medscape; Merck; Mirati Therapeutics; PER; PharmaMar; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Beigene; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; Medscape; Merck Serono; Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA; Mirati Therapeutics; Novartis; PER; Pfizer; PharmaMar; Roche; Sanofi; Servier; Takeda
Research Funding - Alkermes; Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; IO Biotech; Janssen-Cilag; Lilly; Merck Sharp and Dohme LLC, a subsidiary of Merck and Co., Inc, Rahway, NJ USA; Novartis; Pfizer; PharmaMar; Roche; Sanofi; Takeda; Tesaro
A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Mariona Calvo
Consulting or Advisory Role - Bayer; Eisai; MSD; Roche
Other Relationship - Nerviano Medical Sciences
 
Konstantin Penkov
Research Funding - AstraZeneca; BeiGene; GlaxoSmithKline; H3 Biomedicine; Janssen; Nektar; Novartis; Pfizer; Regeneron; Sanofi
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Irene Moreno Candilejo
No Relationships to Disclose
 
Neal D. Shore
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Sanofi; CG Oncology; CG Oncology; Clarity Pharmaceuticals; Clovis Oncology; Dendreon; Exact Imaging; Exact Sciences; FerGene; Ferring; Foundation Medicine; Genesis Cancer Care; Genzyme; Genzyme; InVitae; Janssen Scientific Affairs; Lantheus Medical Imaging; Lilly; MDxHealth; Medivation/Astellas; Merck; Myovant Sciences; Myriad Genetics; Nymox; Pacific Edge Biotechnology; Peerview; Pfizer; Phosphorus; Photocure; Propella Therapeutics; Sanofi; Sema4; Sesen Bio; Speciality Networks; Telix Pharmaceuticals; Tempus; Tolmar; Urogen pharma; Vaxiion
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Clovis Oncology; Dendreon; Foundation Medicine; Guardant Health; Janssen; Merck; Pfizer
Research Funding - Abbvie; Advantagene; Amgen; Aragon Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; Boston Scientific; Bristol-Myers Squibb/Pfizer; CG Oncology; Clovis Oncology; Dendreon; DisperSol; Endocyte; Exact Imaging; Exelixis; Ferring; FKD Therapies; FORMA Therapeutics; Foundation Medicine; Genentech; Guardant Health; InVitae; Istari Oncology; Janssen; Jiangsu Yahong Meditech; MDxHealth; Medivation; Merck; MT Group; Myovant Sciences; Myriad Genetics; Novartis; Nymox; OncoCellMDx; ORIC Pharmaceuticals; pacific edge; Palette Life Sciences; Pfizer; Plexxikon; POINT Biopharma; Propella Therapeutics; Propella Therapeutics; RhoVac; Sanofi; Seagen; Sesen Bio; Steba Biotech; Theralase; Tolmar; Urogen pharma; Urotronic; US Biotest; Vaxiion; Veru; Zenflow
Expert Testimony - Ferring
Other Relationship - Alessa Therapeutics; Photocure
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Aptitude Health; Clinical Care Options; Curio Science; MJH Life Sciences; Pacific Genuity; Peerview
Consulting or Advisory Role - Aravive; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; Exelixis; Janssen; Lilly; Merck; Pfizer; QED Therapeutics; Sanofi/Aventis; Seagen
Speakers' Bureau - Genomic Health; Sanofi/Aventis
Research Funding - Astellas Pharma; Janssen (Inst); Loxo/Lilly (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Pfizer (Inst); Regeneron (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Janssen
 
Begoña Mellado-Gonzalez
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Janssen; Novartis; Pfizer; Roche; Sanofi
Research Funding - Bayer; Janssen; Pfizer; Roche
Travel, Accommodations, Expenses - Janssen; Pfizer
 
Teresa Alonso Gordoa
No Relationships to Disclose
 
Luis Paz-Ares Rodriguez
No Relationships to Disclose
 
Stefano R. Tarantolo
No Relationships to Disclose
 
Juan José Soto
Speakers' Bureau - Novartis; PharmaMar
 
Robert S. Alter
Consulting or Advisory Role - Bayer; Eisai; Janssen Biotech
Speakers' Bureau - Astellas Pharma; Aveo; Bayer; Bristol-Myers Squibb; Exelixis; Gilead Sciences; Pfizer
 
Claudia Andreu-Vieyra
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Timothy Bowler
No Relationships to Disclose
 
Arnab K Maity
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Subramanian Hariharan
Employment - Pfizer
Stock and Other Ownership Interests - pfizer
 
Michael Thomas Schweizer
Consulting or Advisory Role - AstraZeneca; PharmaIn; Resverlogix; Sanofi
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); SignalOne Bio (Inst); Tmunity Therapeutics, Inc. (Inst); Zenith Epigenetics (Inst)